136 related articles for article (PubMed ID: 6321816)
1. Vasopressin as a possible contributor to hypertension.
Yazaki Y; Ohuchi Y; Ashida T; Tsai R; Yoshizumi M
Jpn Circ J; 1984 Feb; 48(2):188-95. PubMed ID: 6321816
[TBL] [Abstract][Full Text] [Related]
2. The importance of vasopressin in the mechanism maintaining hypertension in the rat.
Yazaki Y; Ohuchi Y; Ashida T; Saito T
Jpn Circ J; 1981 Sep; 45(9):1116-20. PubMed ID: 7300021
[TBL] [Abstract][Full Text] [Related]
3. Vasopressin and water distribution in rats with DOCA-salt hypertension.
Kunes J; Nedvídek J; Zicha J
J Hypertens Suppl; 1989 Dec; 7(6):S204-5. PubMed ID: 2632718
[TBL] [Abstract][Full Text] [Related]
4. Antidiuretic and pressor actions of vasopressin in age-dependent DOCA-salt hypertension.
Zicha J; Kunes J; Lébl M; Pohlová I; Slaninová J; Jelínek J
Am J Physiol; 1989 Jan; 256(1 Pt 2):R138-45. PubMed ID: 2912206
[TBL] [Abstract][Full Text] [Related]
5. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats.
Nishimura M; Ohtsuka K; Sakamoto M; Nanbu A; Takahashi H; Yoshimura M
J Hypertens; 1998 Aug; 16(8):1175-85. PubMed ID: 9794722
[TBL] [Abstract][Full Text] [Related]
6. Role of endothelin and vasopressin in DOCA-salt hypertension.
Yu M; Gopalakrishnan V; McNeill JR
Br J Pharmacol; 2001 Apr; 132(7):1447-54. PubMed ID: 11264238
[TBL] [Abstract][Full Text] [Related]
7. Central vasopressin is required for the complete development of deoxycorticosterone-salt hypertension in rats with hereditary diabetes insipidus.
Liang J; Toba K; Ouchi Y; Nagano K; Akishita M; Kozaki K; Ishikawa M; Eto M; Orimo H
J Auton Nerv Syst; 1997 Jan; 62(1-2):33-9. PubMed ID: 9021647
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin-central nervous system interactions in the development of DOCA hypertension.
Berecek KH; Barron KW; Webb RL; Brody MJ
Hypertension; 1982; 4(3 Pt 2):131-7. PubMed ID: 7068203
[TBL] [Abstract][Full Text] [Related]
9. Pressor responses to vasopressin in pigs and sheep with DOCA hypertension.
Ling WD; Brooks DP; Crofton JT; Share L; Bohr DF
Am J Physiol; 1989 Jan; 256(1 Pt 2):H101-4. PubMed ID: 2912171
[TBL] [Abstract][Full Text] [Related]
10. Vascular binding sites and biological activity of vasopressin in DOCA-salt hypertensive rats.
Larivière R; St-Louis J; Schiffrin EL
J Hypertens; 1988 Mar; 6(3):211-7. PubMed ID: 3283226
[TBL] [Abstract][Full Text] [Related]
11. Pressor responsiveness to vasopressin in the rat with DOC-salt hypertension.
Crofton JT; Share L; Wang BC; Shade RE
Hypertension; 1980; 2(4):424-31. PubMed ID: 7399626
[TBL] [Abstract][Full Text] [Related]
12. Effect of acute vasopressin infusion on blood pressure and plasma angiotensin II in normotensive and DOCA-salt hypertensive rats.
Morton JJ; Garcia del Rio C; Hughes MJ
Clin Sci (Lond); 1982 Feb; 62(2):143-9. PubMed ID: 7053914
[TBL] [Abstract][Full Text] [Related]
13. Contribution of vasopressin to hypertension.
Share L; Crofton JT
Hypertension; 1982; 4(5 Pt 2):III85-92. PubMed ID: 7049934
[TBL] [Abstract][Full Text] [Related]
14. The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat.
Crofton JT; Share L; Shade RE; Lee-Kwon WJ; Manning M; Sawyer WH
Hypertension; 1979; 1(1):31-8. PubMed ID: 544512
[TBL] [Abstract][Full Text] [Related]
15. Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension.
Fernandes S; Bruneval P; Hagege A; Heudes D; Ghostine S; Bouby N
Endocrinology; 2002 Jul; 143(7):2759-66. PubMed ID: 12072411
[TBL] [Abstract][Full Text] [Related]
16. Effect of chronic angiotensin-converting enzyme blockade on pressor responses to exogenous angiotensin II, noradrenaline and vasopressin in deoxycorticosterone acetate salt (DOCA)-induced hypertensive rats.
Gan EK; Abas A; Latiff A
Jpn J Pharmacol; 1984 Oct; 36(2):147-51. PubMed ID: 6096611
[TBL] [Abstract][Full Text] [Related]
17. Reduced contractile sensitivity and vasopressin receptor affinity in DOCA-salt hypertension.
Bockman CS; Jeffries WB; Pettinger WA; Abel PW
Am J Physiol; 1992 Jun; 262(6 Pt 2):H1752-8. PubMed ID: 1535757
[TBL] [Abstract][Full Text] [Related]
18. Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension.
Möhring J; Möhring B; Petri M; Haack D
Am J Physiol; 1977 Mar; 232(3):F260-9. PubMed ID: 842673
[TBL] [Abstract][Full Text] [Related]
19. The significance of vasopressin as a pressor agent.
Hofbauer KG; Studer W; Mah SC; Michel JB; Wood JM; Stalder R
J Cardiovasc Pharmacol; 1984; 6 Suppl 2():S429-38. PubMed ID: 6206352
[TBL] [Abstract][Full Text] [Related]
20. Enhanced vasopressin (V2-receptor)-induced sodium retention in mineralocorticoid hypertension.
Jeffries WB; Wang Y; Pettinger WA
Am J Physiol; 1988 May; 254(5 Pt 2):F739-46. PubMed ID: 2834967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
